The evolution of clinical training pathways

The clinical research profession’s learning environment has changed dramatically – with a shift from less well specified training routes to new forms of development opportunities, for example the the Pharmaceutical Medicine Specialty Training run by the Faculty of Pharmaceutical Medicine (FPM). These new training paths are more flexible, practical and use modular approaches, developing the knowledge needed to practice modern clinical pharmacology and empowering medics to master different therapy areas. Trainees are prepared to work in the realities of a clinical career, research, or drug development. 

Dr Lorch has been personally involved in the development of these new types of clinical training. She is a member of the trailblazer group developing the MSc Apprenticeship for Clinical Pharmacology Scientists within the Clinical Pharmacology Skills Alliance alongside the BPS and ABPI. Ulrike has also inputted into the development of the new FPM PMST specialty training curriculum and assessment.

Benefiting our macro environment

All these changes to pharmacological development bring benefits to the sector and the UK in general. Investing in a specialised workforce is crucial to companies like Richmond Pharmacology. It enables us to conduct the most advanced trials, retaining and developing the skills that bring us an advantage in delivering ground-breaking early phase clinical research. 

Constant change within the science and research environment needs a flexible workforce. It is therefore important to build curricula that are tailored for future ways of working within the sector. 

Read Dr Lorch’s full article in PharmaTimes here

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event